Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival

The prognosis of follicular lymphoma could vary with the tumor immune microenvironment. We evaluated the prognostic value of serum levels of ten cytokines. Our study cohort included 60 follicular lymphoma patients and 20 controls. Serum was available at diagnosis in 31 patients, at first relapse in 18, and complete remission in 11. Bioplex technology was used for determination of nine cytokines [interleukin (IL)-1Ra, IL-6, IL-7, IL-10, IL-13, tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (b-FGF)]. Transforming growth factor beta (TGF-β) was measured by sandwich enzyme-linked immunosorbent assay. IL-1Ra, IL-6, IL-7, IL-10, IL-13, TNF-α, VEGF, and PDGF levels were found increased in follicular lymphoma patients compared to controls. Multivariate analysis identified early stage and high TGF-β levels as independent predictors of overall survival associated with improved outcome. High lactate dehydrogenase and VEGF levels were independently associated with poorer progression-free survival. These results show the prognostic value of TGF-β and VEGF in follicular lymphoma and suggest their contribution to tumor microenvironment alterations.

[1]  Y. Lévy,et al.  Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. , 1994, The Journal of clinical investigation.

[2]  H. Johnsen,et al.  Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma , 2005, Annals of Hematology.

[3]  D. Lebman,et al.  The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. , 1999, Microbes and infection.

[4]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[5]  Donna Neuberg,et al.  Center B Cells Using Cdna Arrays Gene Expression Profiling of Follicular Lymphoma and Normal Germinal , 2002 .

[6]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[7]  Emili Montserrat,et al.  High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.

[8]  K. Ganjoo.  Antiangiogenesis: A new approach to the treatment of lymphoma , 2007, Leukemia & lymphoma.

[9]  H. Joensuu,et al.  Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.

[10]  F. B. Sørensen,et al.  Angiogenesis in non-Hodgkin's lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes , 2007, Leukemia & lymphoma.

[11]  G. Salles,et al.  Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.

[12]  D. Lebman,et al.  The role of TGF-β in growth, differentiation, and maturation of B lymphocytes , 1999 .

[13]  M. Calaminici,et al.  Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Blay,et al.  Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Cerhan,et al.  Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. , 2007, Blood.

[17]  D. Vignali.  Multiplexed particle-based flow cytometric assays. , 2000, Journal of immunological methods.

[18]  R. Kurzrock,et al.  High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. , 1998, Leukemia & lymphoma.

[19]  L. Rimsza,et al.  Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108 , 2005 .

[20]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[21]  D. Scadden,et al.  Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. , 1995, Blood.

[22]  D. de Jong.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Salles,et al.  High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[25]  G. Ayers,et al.  Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Caligiuri,et al.  A review of the association between interleukin-10 and human B-cell malignancies , 1998, Cancer Immunology, Immunotherapy.

[27]  A. Wyllie,et al.  T Cell Death and Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.

[28]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[29]  J. Blay,et al.  Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.

[30]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[31]  G. Salles.  Clinical features, prognosis and treatment of follicular lymphoma. , 2007, Hematology. American Society of Hematology. Education Program.